Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 127

1.

Ceftaroline-heteroresistant Staphylococcus aureus.

Saravolatz SN, Martin H, Pawlak J, Johnson LB, Saravolatz LD.

Antimicrob Agents Chemother. 2014 Jun;58(6):3133-6. doi: 10.1128/AAC.02685-13. Epub 2014 Mar 17.

3.

Antimicrobial activity of ceftaroline tested against staphylococci with reduced susceptibility to linezolid, daptomycin, or vancomycin from U.S. hospitals, 2008 to 2011.

Sader HS, Flamm RK, Jones RN.

Antimicrob Agents Chemother. 2013 Jul;57(7):3178-81. doi: 10.1128/AAC.00484-13. Epub 2013 Apr 29.

4.
5.

Activity of ceftaroline and epidemiologic trends in Staphylococcus aureus isolates collected from 43 medical centers in the United States in 2009.

Richter SS, Heilmann KP, Dohrn CL, Riahi F, Costello AJ, Kroeger JS, Biek D, Critchley IA, Diekema DJ, Doern GV.

Antimicrob Agents Chemother. 2011 Sep;55(9):4154-60. doi: 10.1128/AAC.00315-11. Epub 2011 Jun 27.

6.
7.

In vitro evaluation of ceftaroline alone and in combination with tobramycin against hospital-acquired meticillin-resistant Staphylococcus aureus (HA-MRSA) isolates.

Vidaillac C, Leonard SN, Rybak MJ.

Int J Antimicrob Agents. 2010 Jun;35(6):527-30. doi: 10.1016/j.ijantimicag.2010.02.006. Epub 2010 Mar 26.

PMID:
20346632
8.

Activity of ceftobiprole against methicillin-resistant Staphylococcus aureus strains with reduced susceptibility to daptomycin, linezolid or vancomycin, and strains with defined SCCmec types.

Farrell DJ, Flamm RK, Sader HS, Jones RN.

Int J Antimicrob Agents. 2014 Apr;43(4):323-7. doi: 10.1016/j.ijantimicag.2013.11.005. Epub 2013 Dec 11.

PMID:
24411474
9.

Clinical implications of vancomycin heteroresistant and intermediately susceptible Staphylococcus aureus.

Gomes DM, Ward KE, LaPlante KL.

Pharmacotherapy. 2015 Apr;35(4):424-32. doi: 10.1002/phar.1577. Review.

PMID:
25884530
10.

In vitro pharmacodynamics of human simulated exposures of ceftaroline and daptomycin against MRSA, hVISA, and VISA with and without prior vancomycin exposure.

Bhalodi AA, Hagihara M, Nicolau DP, Kuti JL.

Antimicrob Agents Chemother. 2014;58(2):672-7. doi: 10.1128/AAC.01516-13. Epub 2013 Nov 11.

12.

In vivo development of daptomycin resistance in vancomycin-susceptible methicillin-resistant Staphylococcus aureus severe infections previously treated with glycopeptides.

Capone A, Cafiso V, Campanile F, Parisi G, Mariani B, Petrosillo N, Stefani S.

Eur J Clin Microbiol Infect Dis. 2016 Apr;35(4):625-31. doi: 10.1007/s10096-016-2581-4. Epub 2016 Jan 27.

PMID:
26815434
13.

Prevalence of vancomycin-intermediate Staphylococcus aureus (VISA) and heterogeneous VISA among methicillin-resistant S. aureus with high vancomycin minimal inhibitory concentrations in Taiwan: A multicenter surveillance study, 2012-2013.

Huang SH, Chen YC, Chuang YC, Chiu SK, Fung CP, Lu PL, Wang LS, Wu TL, Wang JT.

J Microbiol Immunol Infect. 2016 Oct;49(5):701-707. doi: 10.1016/j.jmii.2015.07.003. Epub 2015 Jul 31.

14.
16.

Activity of ceftaroline against extracellular (broth) and intracellular (THP-1 monocytes) forms of methicillin-resistant Staphylococcus aureus: comparison with vancomycin, linezolid and daptomycin.

Mélard A, Garcia LG, Das D, Rozenberg R, Tulkens PM, Van Bambeke F, Lemaire S.

J Antimicrob Chemother. 2013 Mar;68(3):648-58. doi: 10.1093/jac/dks442. Epub 2012 Nov 27.

PMID:
23188792
17.

Vancomycin and daptomycin minimum inhibitory concentration distribution and occurrence of heteroresistance among methicillin-resistant Staphylococcus aureus blood isolates in Turkey.

Sancak B, Yagci S, Gür D, Gülay Z, Ogunc D, Söyletir G, Yalcin AN, Dündar DO, Topçu AW, Aksit F, Usluer G, Ozakin C, Akalin H, Hayran M, Korten V.

BMC Infect Dis. 2013 Dec 10;13:583. doi: 10.1186/1471-2334-13-583.

18.

[Investigation of antibiotic resistance patterns and reduced vancomycin susceptibilities of methicillin-resistant Staphylococcus aureus isolates: a multi-center study].

Çıkman A, Aydın M, Gülhan B, Parlak M, Gültepe B, Kalaycı Y, Bayındır Bilmen F, Solmaz S, Özekinci T.

Mikrobiyol Bul. 2015 Apr;49(2):240-8. Turkish.

19.

Oritavancin Combinations with β-Lactams against Multidrug-Resistant Staphylococcus aureus and Vancomycin-Resistant Enterococci.

Smith JR, Yim J, Raut A, Rybak MJ.

Antimicrob Agents Chemother. 2016 Mar 25;60(4):2352-8. doi: 10.1128/AAC.03006-15. Print 2016 Apr.

20.

Clinical and Microbiological Characteristics of Heteroresistant and Vancomycin-Intermediate Staphylococcus aureus from Bloodstream Infections in a Brazilian Teaching Hospital.

da Costa TM, Morgado PG, Cavalcante FS, Damasco AP, Nouér SA, Dos Santos KR.

PLoS One. 2016 Aug 30;11(8):e0160506. doi: 10.1371/journal.pone.0160506. eCollection 2016.

Supplemental Content

Support Center